Tudor domain-containing protein 9-targeting siRNA nanoparticles alleviate Pseudomonas aeruginosa lung injury in preclinical models by promoting neutrophil cuproptosis - PubMed
5 days ago
- #Pseudomonas aeruginosa
- #nanoparticles
- #neutrophil cuproptosis
- Pseudomonas aeruginosa pneumonia is a significant therapeutic challenge.
- Hyaluronic acid (HA)-coated peptide nanoparticles deliver siRNA against Tudor domain-containing protein 9 (TDRD9).
- TDRD9-silenced polymorphonuclear neutrophils reduce lung inflammation and edema in mice.
- TDRD9 suppresses neutrophil cuproptosis by upregulating PD-L1 through CD80 interaction, activating p38 MAPK signaling.
- HA-si-TDRD9 nanoparticles enhance neutrophil cuproptosis and reduce pulmonary neutrophil accumulation.
- HA-si-TDRD9 nanoparticles reduce bacterial growth, apoptosis, and inflammation in human lung organoids.
- Targeting TDRD9 with siRNA nanoparticles is a promising strategy for bacterial lung injury treatment.